WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205815
Description: Armodafinil is discontinued (DEA controlled substance). Armodafinil, also known as CEP-10953, is the R-enantiomer of the racemic synthetic agent Modafinil with central nervous system (CNS) stimulant and wakefulness-promoting activities. Armodafinil appears to inhibit the reuptake of dopamine by binding to the dopamine-reuptake pump, which leads to an increase in extracellular dopamine levels in some brain regions. This agent does not bind to or inhibit several receptors and enzymes that may be involved in sleep/wake regulation and is not a direct- or indirect-acting dopamine receptor agonist.
MedKoo Cat#: 205815
Chemical Formula: C15H15NO2S
Exact Mass: 273.08235
Molecular Weight: 273.3501
Elemental Analysis: C, 65.91; H, 5.53; N, 5.12; O, 11.71; S, 11.73
Armodafinil is discontinued (DEA controlled substance).
Synonym: CEP-10953; CEP 10953; CEP10953; CRL 40982; CRL-40982; CRL40982; Armodafinil; brand name: Nuvigil.
IUPAC/Chemical Name: 2-[(R)-(diphenylmethyl)sulfinyl]acetamide
InChi Key: YFGHCGITMMYXAQ-LJQANCHMSA-N
InChi Code: InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1
SMILES Code: O=C(N)C[S@](C(C1=CC=CC=C1)C2=CC=CC=C2)=O
The following data is based on the product molecular weight 273.3501 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Kim D. Practical use and risk of modafinil, a novel waking drug. Environ Health Toxicol. 2012;27:e2012007. Epub 2012 Feb 22. PubMed PMID: 22375280; PubMed Central PMCID: PMC3286657.
2: Gehring K, Roukema JA, Sitskoorn MM. Review of recent studies on interventions for cognitive deficits in patients with cancer. Expert Rev Anticancer Ther. 2012 Feb;12(2):255-69. PubMed PMID: 22316373.
3: Tejedor MA, Rubiales AS, MartÃnez M, CortÃ©s CC. [Asthenia in advanced cancer and the use of psychostimulants]. An Sist Sanit Navar. 2011 Sep-Dec;34(3):471-9. Spanish. PubMed PMID: 22233850.
4: Sugden C, Housden CR, Aggarwal R, Sahakian BJ, Darzi A. Effect of pharmacological enhancement on the cognitive and clinical psychomotor performance of sleep-deprived doctors: a randomized controlled trial. Ann Surg. 2012 Feb;255(2):222-7. PubMed PMID: 21997802.
5: Pruitt AA. Medical management of patients with brain tumors. Curr Treat Options Neurol. 2011 Aug;13(4):413-26. PubMed PMID: 21557041.
6: Campos MP, Hassan BJ, Riechelmann R, Del Giglio A. Cancer-related fatigue: a review. Rev Assoc Med Bras. 2011 Apr;57(2):211-9. Review. English, Portuguese. PubMed PMID: 21537710.
7: Portela MA, Rubiales AS, Centeno C. The use of psychostimulants in cancer patients. Curr Opin Support Palliat Care. 2011 Jun;5(2):164-8. Review. PubMed PMID: 21532350.
8: Crowley RK, Woods C, Fleming M, Rogers B, Behan LA, O'Sullivan EP, Kane T, Agha A, Smith D, Costello RW, Thompson CJ. Somnolence in adult craniopharyngioma patients is a common, heterogeneous condition that is potentially treatable. Clin Endocrinol (Oxf). 2011 Jun;74(6):750-5. doi: 10.1111/j.1365-2265.2011.03993.x. PubMed PMID: 21521265.
9: Adams C, McKeon A, Silber MH, Kumar R. Narcolepsy, REM sleep behavior disorder, and supranuclear gaze palsy associated with Ma1 and Ma2 antibodies and tonsillar carcinoma. Arch Neurol. 2011 Apr;68(4):521-4. Erratum in: Arch Neurol. 2011 Sep;68(9):1211. PubMed PMID: 21482933.
10: De Waele S, Van Belle S. Cancer-related fatigue. Acta Clin Belg. 2010 Nov-Dec;65(6):378-85. Review. PubMed PMID: 21268950.
Armodafinil is an enantiopure drug consisting of just the active (−)-(R)-enantiomer of the racemic drug modafinil (Provigil). Armodafinil is approved by the FDA for the treatment of narcolepsy and shift work sleep disorder, and as an adjunctive treatment for obstructive sleep apnea. Cephalon plans to conduct clinical trials evaluating the use of Nuvigil as a treatment for serious medical conditions such as bipolar depression and fatigue in conditions such as Parkinson's disease and cancer. In June, 2010, it was revealed that a phase II study of armodafinil as an adjunctive therapy in adults with schizophrenia had failed to meet the primary endpoints, and the clinical program was subsequently ceased. The drug was being considered for the first FDA-approved medicinally-specific drug for combating jet-lag. but on March 30, 2010, the FDA declined to approve use of Nuvigil to treat jet lag. (source: http://en.wikipedia.org/wiki/Armodafinil).